HH-30134

N/A

Report date: 2023/04/04 20:00:35
NME

Base Information

Drug NameHH-30134
Drug Alias NameHH-30134
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsAXL receptor tyrosine kinase inhibitorsNerve growth factor receptor Trk-A antagonists
TargetsAXL receptor tyrosine kinaseNerve growth factor receptor Trk-ATyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesShangHai HaiHe Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesHaihe Biopharma (HK) LtdShangHai HaiHe Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A